New to Substance Over Noise? Start here.
Evidence-based obesity medicine, minus the noise. Begin
I Put Twelve GLP-1 Trials on One Page
The evidence that actually holds up in 2026 — weight loss, heart, kidney, muscle, and the myths that should have died already. Free one-page reference inside.
GLP1
+2
The PCSK9 Pill Is Here. The Needle Was the Barrier.
The FDA approved the first oral PCSK9 inhibitor — antibody-class LDL-C lowering from a once-daily tablet. Here is what it does, and the one thing it hasn't proven yet.
Lipids
+1
SPECIAL EDITION: Nobody Asked.
A new JAMA secret-shopper study bought 45 GLP-1 prescriptions online. Most arrived in a day. Some in under 5 minutes. Almost none asked the questions that keep patients safe. I have watched this happen from the inside, and I know exactly why.
GLP1
+2
I Built a Live Index of Every Obesity Drug Trial
The pipeline moves faster than any newsletter can. So I stopped trying to summarize it and built something that updates itself.
GLP1
+1
Obesity Medicine Stopped Being a Horse Race
Nine drugs, four receptors, and two new pills into 2026, the field is quietly reorganizing around a better question. Not how much weight. Which disease.
GLP1
+2
The Basics
Appetite, Food Noise, and What We’ve Been Getting
Why Weight Returns After Stopping GLP-1
The Controversies
The Peptide Wild West (Part I)
I’ve Been Taking Low-Dose Tirzepatide for Two
Obesity Care: I Was
The Future
Medicare Will Pay for Wegovy Now. Here’s the Catch.
How Much Muscle Are GLP-1 Patients Actually Losing?
GLP-1 Resistance Is Real. You Probably Don’t Have It.